+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Zika Virus Infection - Pipeline Insight, 2021

  • ID: 5310609
  • Clinical Trials
  • October 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Annexin A5
  • Bemcentinib
  • BIT 009
  • EMX 001
  • GLS-5700
  • INO-A002
This “Zika Virus Infection - Pipeline Insight, 2021” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered


  • Global coverage

Zika Virus Infection Understanding


Zika Virus Infection: Overview


Zika fever is a mosquito-borne viral disease caused by Zika virus (ZIKV), consisting of mild fever, rash (mostly maculo-papular), headaches, arthralgia, myalgia, asthenia, and non-purulent conjunctivitis, occurring about two to seven days after the mosquito vector bite. Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). The symptoms typically last for 2-7 days. The diagnosis of the virus is done through a blood test. Zika virus infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations, known as congenital Zika syndrome. Infection with Zika virus is also associated with other complications of pregnancy including preterm birth and miscarriage. Treatment consists of relieving pain, fever, and any other symptom that inconveniences the patient. To prevent dehydration, it is recommended to control the fever, rest, and drink plenty of water.

"Zika Virus Infection - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Zika Virus Infection pipeline landscape is provided which includes the disease overview and Zika Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Zika Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Zika Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Zika Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Zika Virus Infection.

Zika Virus Infection Emerging Drugs Chapters


This segment of the Zika Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Zika Virus Infection Emerging Drugs


mRNA-1893: Moderna Therapeutics


mRNA-1893 contains an mRNA sequence encoding for the structural proteins of the Zika virus and is designed to cause cells to secrete virus-like particles, mimicking the response of the cell after natural infection. The drug is in Phase II clinical studies for the treatment of Zika Virus Infection. In August 2019, Moderna announced that the US FDA has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) for the prevention of Zika virus infection in healthy adults.

GLS-5700: GeneOne Life Science


GLS-5700 is a DNA vaccine encoding the pre-membrane and envelop (prM-E) proteins of Zika virus (ZIKV). It is being developed by Geneone life science for Zika Virus Infection and is currently in Phase I stage of development.

Zika Virus Infection: Therapeutic Assessment


This segment of the report provides insights about the different Zika Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Zika Virus Infection


There are approx. 12+ key companies which are developing the therapies for Zika Virus Infection. The companies which have their Zika Virus Infection drug candidates in the most advanced stage, i.e. Phase II include, Moderna Therapeutics.

Phases


This report covers around 12+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Zika Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as


  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as


  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Zika Virus Infection: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Zika Virus Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Zika Virus Infection drugs.

Zika Virus Infection Report Insights


  • Zika Virus Infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Zika Virus Infection Report Assessment


  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Zika Virus Infection drugs?
  • How many Zika Virus Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Zika Virus Infection?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Zika Virus Infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Zika Virus Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players


  • Moderna Therapeutics
  • GeneOne Life Science
  • WuXi Biologics
  • Inovio Pharmaceuticals
  • Takeda
  • Emergex Vaccines
  • Rigel Pharmaceuticals
  • Ala Wai Pharma Australia
  • Immunomodulation
  • Greffex
  • Biotron

Key Products


  • mRNA 1893
  • GLS-5700
  • Tyzivumab
  • INO-A002
  • TAK 426
  • EMX 001
  • Bemcentinib
  • Niclosamide
  • Annexin A5

Research programme: DNA vaccines

  • BIT 009
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Annexin A5
  • Bemcentinib
  • BIT 009
  • EMX 001
  • GLS-5700
  • INO-A002

IntroductionExecutive Summary
Zika Virus Infection: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Zika Virus Infection - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

mRNA 1893: Moderna Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

Tyzivumab: Tychan/WuXi Biologics
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical and Discovery Stage Products
  • Comparative Analysis

EMX 001: Emergex Vaccines
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Zika Virus Infection Key CompaniesZika Virus Infection Key ProductsZika Virus Infection- Unmet NeedsZika Virus Infection- Market Drivers and BarriersZika Virus Infection- Future Perspectives and ConclusionZika Virus Infection Analyst ViewsAppendix
List of Tables
Table 1 Total Products for Zika Virus Infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Zika Virus Infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • mRNA 1893
  • GLS-5700
  • Tyzivumab
  • INO-A002
  • TAK 426
  • EMX 001
  • Bemcentinib
  • Niclosamide
  • Annexin A5
  • Research programme: DNA vaccines
  • BIT 009
Note: Product cover images may vary from those shown